Comparative Efficacy of Ovule vs Tablet

Condition(s) targeted: Clotrimazole,; Ovulen,; Vulvovaginal Candidiasis

Intervention: Clotrimazole, vaginal ovule (Drug); Clotrimazole, vaginal tablet (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer

Overall contact:
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com

The study is focused to prove that the efficacy of a new Canesten formulation (ovule) is not inferior to the old Canesten formulation (tablet)

Official title: An Investigator-Blinded, Active-Controlled Phase 3 Study to Prove the Non-Inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis

Study design: Treatment, Randomized, Single Blind (Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Subjects with mycological and clinical cure

Secondary outcome:

Subjects with mycological and clinical cure

Clinical cure

Clinical cure

Mycological cure

Mycological cure

Minimum age: 14 Years. Maximum age: 50 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Non-pregnant females aged at least 14 years in Germany or at least 16 years in Russia

and not older than 50 years.

- Subjects presenting a symptomatic vulvovaginal yeast infection confirmed by

microscopic evaluation (wet mount preparation).

- Subjects must be cooperative, able to understand the requirements of the trial

participation, and willing to participate in the trial. For adolescents the informed consent has to be provided to a legal representative in addition.

- Subjects of childbearing potential must use an acceptable method of contraception.

Hormonal or oral contraceptive drugs, intra-uterine devices (IUD) and abstinence are considered acceptable methods of contraception.

- Negative saline smear for Trichomonas vaginalis

Exclusion Criteria:

- Subjects with known hypersensitivity to imidazoles or triazoles and their analogues.

- Subjects presenting a protozoan infection as confirmed by microscopic investigation.

- Pregnant, breast feeding or lactating subjects.

- Subjects with suspected bacterial vaginal infection.

- Subjects with abdominal pain, fever, or foul smelling vaginal discharge.

- Subjects who had a vaginal infection, or who had used an intravaginal or systemic

antimycotic treatment within 60 days prior to visit 1.

- Subjects using or wishing to use intra-vaginal or systemic anti-infectives or systemic

antifungal therapy during the trial.

- Subjects wishing to use contraceptive foams, creams, jellies, sponges, therapeutic

ointments, condoms, diaphragms, and OTC vaginal products during treatment and 3 days thereafter (i. e. until day 4).

- Subjects unable to refrain from the use of vaginal tampons during treatment and for 3

days thereafter (i. e. until day 4).

- Subjects unable to refrain from the use of feminine hygiene products (e. g. douches,

feminine deodorant products) for 2 weeks (i. e. from visit 1 until visit 2).

- Subjects suffering from chronic/recurrent vulvovaginal mycosis, defined as 4 or more

mycologically proven symptomatic episodes during the last 12 months.

- Subjects suffering from diseases (e. g. diabetes, decreased cellular immunity) or being

treated with drugs (e. g. immunosuppressants, corticosteroids, anti-infectives) which may predispose them to mycological infections.

- Subjects who received another investigational drug within 30 days before visit 1.

- Unwillingness to refrain from sexual activity during 3 days thereafter.

- Actual menstruation at visit 1 or expected menstruation within 4 days after visit 1.

Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com

Hamburg 22159, Germany; Not yet recruiting

Hamburg 22359, Germany; Not yet recruiting

Moscow 127473, Russian Federation; Recruiting

Moscow 119002, Russian Federation; Recruiting

Moscow 129090, Russian Federation; Recruiting

Moscow 117997, Russian Federation; Terminated

Moscow 117997, Russian Federation; Recruiting

Moscow 117198, Russian Federation; Not yet recruiting

Moscow 117415, Russian Federation; Recruiting

Freiburg, Baden-Württemberg 79106, Germany; Recruiting

München, Bayern 85356, Germany; Recruiting

München, Bayern 80333, Germany; Recruiting

Fulda, Hessen 36037, Germany; Not yet recruiting

Frankfurt, Hessen 65929, Germany; Not yet recruiting

Osnabrück, Niedersachsen 49074, Germany; Recruiting

Hannover, Niedersachsen 30459, Germany; Not yet recruiting

Click here and search for drug information provided by the FDA

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product

Click here to find results for studies related to marketed products

Starting date: September 2008
Ending date: May 2009
Last updated: January 26, 2009